{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:05:19Z","timestamp":1779433519607,"version":"3.53.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypoactive Sexual Desire Disorder (HSDD) is a prevalent and distressing condition affecting adult women and is associated with significant impairments in quality of life and interpersonal relationships. Despite increasing recognition of female sexual health as a clinical priority, pharmacological treatment options for HSDD remain limited, and evidence from individual clinical trials remains heterogeneous. Therefore, a systematic evaluation of registered clinical trials is essential to better understand therapeutic development, efficacy endpoints, and safety profiles of emerging treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This systematic review was conducted in accordance with PRISMA 2020 guidelines using a structured search of\n                      <jats:uri>ClinicalTrials.gov<\/jats:uri>\n                      . Completed interventional clinical trials evaluating pharmacological therapies for HSDD in adult women were identified using predefined eligibility criteria. Data were extracted on study design, participant characteristics, investigational agents, efficacy outcomes related to sexual desire and distress, and reported safety outcomes. Findings were synthesized descriptively without pooled quantitative analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of nine completed pharmacological clinical trials met the inclusion criteria. Most were Phase II and Phase III randomized, double-blind, placebo-controlled studies, primarily enrolling premenopausal women with acquired, generalized HSDD. Investigational therapies predominantly targeted central nervous system pathways, with flibanserin and bremelanotide representing the most extensively studied agents. Efficacy outcomes commonly included validated patient-reported measures such as the Female Sexual Function Index desire domain and the Female Sexual Distress Scale; however, endpoint designation and reporting completeness varied across trials. Safety data were inconsistently reported, with adverse events reflecting the pharmacological mechanisms of the agents studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings highlight both progress and persistent gaps in the pharmacological treatment landscape for HSDD. Variability in trial design, outcome measures, and reporting practices limits cross-trial comparison and clinical interpretation. Further research with standardized methodologies and comprehensive reporting is needed to strengthen the evidence base.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1789809","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:11:09Z","timestamp":1779430269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov"],"prefix":"10.3389","volume":"13","author":[{"given":"Ahmed M.","family":"Ashour","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/jmwh.13283","article-title":"Hypoactive sexual desire disorder in women: physiology, assessment, diagnosis, and treatment","volume":"66","author":"Pettigrew","year":"2021","journal-title":"J Midwifery Womens Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1176\/appi.focus.20200039","article-title":"Treatment of hypoactive sexual desire disorder among women: general considerations and pharmacological options","volume":"19","author":"Pachano Pesantez","year":"2021","journal-title":"Focus"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1089\/jwh.2021.0255","article-title":"Assessing the burden of illness associated with acquired generalized hypoactive sexual desire disorder","volume":"31","author":"Simon","year":"2021","journal-title":"J Womens Health"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1089\/jwh.2019.7865","article-title":"Female hypoactive sexual desire disorder: a practical guide to causes, clinical diagnosis, and treatment","volume":"29","author":"Kingsberg","year":"2020","journal-title":"J Womens Health"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.esxm.2018.01.004","article-title":"Evaluation and Management of Hypoactive Sexual Desire Disorder","volume":"6","author":"Clayton","year":"2018","journal-title":"Sex Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1745506518762664","DOI":"10.1177\/1745506518762664","article-title":"Women's sexual dysfunction associated with psychiatric disorders and their treatment","volume":"14","author":"Basson","year":"2018","journal-title":"Womens Health"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1743-6109.2009.01618.x","article-title":"Psychological and interpersonal dimensions of sexual function and dysfunction","volume":"7","author":"McCabe","year":"2010","journal-title":"J Sex Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/19317611.2021.1926039","article-title":"The prevalence of sexual dysfunction in the different menopausal stages: a systematic review and meta-analysis","volume":"33","author":"Khani","year":"2021","journal-title":"Int J Sex Health"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1743-6109.2012.02818.x","article-title":"Sexual desire and hypoactive sexual desire disorder in women: introduction and overview. Standard operating procedure (SOP part 1)","volume":"10","author":"Bitzer","year":"2012","journal-title":"J Sex Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"qeaf057","DOI":"10.1093\/sxmrev\/qeaf057","article-title":"Evaluation and management of hypoactive sexual desire disorder in women: recommendations from the 5th international consultation on sexual medicine (ICSM 2024)","volume":"12","author":"Rowen","year":"2024","journal-title":"Sex Med Rev"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2217\/17455057.1.2.263","article-title":"Pharmacologic treatment options for hypoactive sexual desire disorder","volume":"6","author":"Bolour","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e38592","DOI":"10.1097\/MD.0000000000038592","article-title":"Role of flibanserin in managing hypoactive sexual desire disorder in women: a systematic review and meta-analysis","volume":"103","author":"Kamrul-Hasan","year":"2024","journal-title":"Medicine"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/sexes6030038","article-title":"Advancing women\u2019s health: a scoping review of pharmaceutical therapies for female sexual dysfunction","volume":"6","author":"Elanjian","year":"2025","journal-title":"Sexes"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/AOG.0000000000003514","article-title":"Long-term safety and efficacy of Bremelanotide for hypoactive sexual desire disorder","volume":"134","author":"Simon","year":"2019","journal-title":"Obstet Gynecol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1111\/jsm.13037","article-title":"Efficacy and safety of Flibanserin in women with hypoactive sexual desire disorder: a systematic review and Meta-analysis","volume":"12","author":"Gao","year":"2015","journal-title":"J Sex Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1111\/jsm.13037","article-title":"Efficacy and safety of flibanserin in women with hypoactive sexual desire disorder: a systematic review and meta-analysis","volume":"12","author":"Thorp","year":"2015","journal-title":"J Sex Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.maturitas.2016.02.009","article-title":"A biopsychosocial approach to women's sexual function and dysfunction at midlife: a narrative review","volume":"87","author":"Thomas","year":"2016","journal-title":"Maturitas"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1111\/j.1743-6109.2010.01871.x","article-title":"Sexual desire and the female sexual function index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder","volume":"7","author":"Gerstenberger","year":"2010","journal-title":"J Sex Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/j.1743-6109.2011.02312.x","article-title":"Content validity of the female sexual function index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder","volume":"8","author":"Revicki","year":"2011","journal-title":"J Sex Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12913-019-4651-7","article-title":"Adverse drug reactions in primary care: a scoping review","volume":"20","author":"Khalil","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/13697137.2021.1891773","article-title":"International Society for the Study of women\u2019s sexual health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women","volume":"24","author":"Parish","year":"2021","journal-title":"Climacteric"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/ijwh.s7578","article-title":"Management of hypoactive sexual desire disorder in women: current and emerging therapies","volume":"2","author":"Nappi","year":"2010","journal-title":"Int J Women's Health"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01076-w","article-title":"Current and future pharmacotherapy for female sexual dysfunction","volume":"23","author":"Reisman","year":"2025","journal-title":"Nat Rev Urol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1002\/jcph.1778","article-title":"Clinical pharmacology in women's health: current status and opportunities","volume":"60","author":"Kim","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/dtb.2021.000020","article-title":"Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent","volume":"59","author":"Mintzes","year":"2021","journal-title":"Drug Ther Bull"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s41687-021-00359-1","article-title":"Psychometric validation of the female sexual distress scale-desire\/arousal\/orgasm","volume":"5","author":"Derogatis","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s41687-020-00241-6","article-title":"Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder","volume":"4","author":"Revicki","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"ref28","first-page":"50","article-title":"Sexual desire disorders","volume":"5","author":"Montgomery","year":"2008","journal-title":"Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/neurolint14010006","article-title":"Bremelanotide for treatment of female hypoactive sexual desire","volume":"14","author":"Edinoff","year":"2022","journal-title":"Neurol Int"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1789809\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:11:19Z","timestamp":1779430279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1789809\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":29,"alternative-id":["10.3389\/fmed.2026.1789809"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1789809","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1789809"}}